🔗 Share this article

An underground economy for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Investigational Drug Gaining Traction Online

The experimental drug, which remains in clinical trials, is being advertised by online personalities for its supposed fat-burning effects. Followers are urged to message these profiles privately for supplier links, while also obtaining discount codes.

Thriving Commerce on Social Networks

Separately, a robust trade exists on messaging services, where communities with numerous of members share comparison photos, injection guides and claims of rapid UK delivery. Sellers market the substance there before redirecting buyers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist individuals lose up to 25% of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Medical Experts Voice Worries

However, doctors and pharmacists have warned that the distribution of what remains an unlicensed drug in the UK is a cause for concern and could result in users administering products of uncertain source.

Several experts said the demand for retatrutide could be linked to the increasing cost of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that must not be promoted or distributed for human use under the British medical regulations.

Several content creators attempt to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and supply can still violate medicines, advertising, and customer laws, risking penalties, prosecution or imprisonment.

Platform Reaction and Material Removal

Based on the social media company, the platform has taken down problematic material and prohibited related hashtags and search suggestions. The company stated it was committed to maintaining the service safe and investing in strengthening enforcement strategies.

Online Marketplace Activities

Research also discovered communities with up to 9,000 members selling retatrutide using the platform's integrated search feature, which functions like a public directory. Typing “retatrutide” instantly displays channels with thousands of users, filled with images of weight loss, positive testimonials and step-by-step guides for preparing or injecting at home.

After minutes of joining one community, a seller posted contact information, where most purchases take place. The vendor sent an guidebook and guaranteed shipping within 48 hours. When asked whether the substance was authentic, one vendor responded: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. None asked about weight, medical conditions or past usage.

Item Information and Pricing

Within these groups, messages display black plastic packages with Royal Mail stickers, stating to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, prepared at home with sterile water, or ready-to-use pens typically sold at 160 pounds for 20 milligrams. When asked how much time a pen should last, sellers give contradictory answers ranging from a several days to “depends on your body”.

Platform Moderation and Safety Measures

A spokesperson for the messaging service stated it actively monitored harmful material on its service including material that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“Individuals are administering substances they can’t verify. Although the research behind this drug is sound, these digital products may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to recent price rises for authorized weight-loss medications such as Mounjaro. “With costs rising, individuals are turning to social media. But fake injections are extremely risky. You cannot know what’s inside or whether the environment they were made in was clean,” she said.

Her team has already seen individuals harmed by self-injection from unverified sources. “We recognize the frustration, but buying from messaging apps or WhatsApp is taking chances with your health,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”

Producer Position

A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any government authority globally. “Consequently at this time no one can market [it] for personal consumption,” they said, adding that any product “falsely representing itself as a company experimental substance not yet approved … may subject patients to possibly serious medical dangers”.